27 C
Vientiane
Sunday, June 1, 2025
spot_img
Home Blog Page 135

The Chinese and French children’s choirs have another musical rendezvous in Paris


WUZHISHAN, CHINA – Media OutReach Newswire – 14 May 2025 – May is a great season to experience the French romance. Nearly 20 members of the Wuzhishan Li & Miao Children’s Choir once again set off in central Hainan Island, China, for a cultural exchange in France.

From May 8 to 10, the Wuzhishan Li & Miao Children's Choir once again set off in central Hainan Island, China, for a cultural exchange in France.
From May 8 to 10, the Wuzhishan Li & Miao Children’s Choir once again set off in central Hainan Island, China, for a cultural exchange in France.

On the evening of May 9 (local time), nearly 300 guests lined up outside Café de la Danse, a theater in downtown Paris, to enjoy the show that highlighted the friendship between the two countries. When the Chinese and French versions of “Sing Wuzhishan to France” alternated, the performance reached its climax, and everyone could not help but clap along to the song. The event ended with “Auld Lang Syne.” Monica, a French audience member, expressed that she was highly impressed and thrilled about the people-to-people exchange.

The repertoire was co-prepared by the Wuzhishan Li & Miao Children’s Choir, Le Choeur des Polysons, La Chorale Chin’harmonie, and Association Vent d’Orient Vent d’Occident.

“Last May, we sang together to celebrate the 60 years of Sino-French diplomacy. Last October, Le Choeur des Polysons performed in Wuzhishan. Children bonded over music and gained a better understanding of each other’s cultures. Today, we reunited in Paris, and I am deeply touched.” Elisabeth Trigo, the head of the Le Choeur des Polysons, said.

Another phenomenal scene was the collaboration between Huang Hailin and Matthieu Lecoq. Hailin is an inheritor of Hainan’s intangible cultural heritage, the nose flute, which is a bamboo instrument of the Li ethnic group. Matthieu is a musician of the Opéra de Paris who uses the flute to demonstrate his love of the history and mythology of Wuzhishan. He stated, “It is a tremendous pleasure working with her for the first time and finding synergy between Chinese and Western music.”

This year marks the 50th anniversary of the establishment of diplomatic ties between China and the EU. The Publicity Department of the Wuzhishan Municipal Party Committee is one of the organizers of this visit event, the Wuzhishan Li & Miao Children’s Choir also visited the UNESCO headquarters, the Cinémathèque Française, and a primary school, not only observing the wonderful diversity of world heritage and experiencing France’s one-of-a-kind arts but also spreading excellent.

Hainan is blessed with abundant natural and cultural resources and has unique potential in adding ‘Hainan Tropical Rainforest and the Traditional Settlement of Li Ethnic Group’ to the UNESCO Heritage List. We hope that Hainan can further integrate resources and strengthen systematic protection and innovative development of intangible cultural heritage, said Wang Ying, Deputy Delegate of the Chinese Permanent Delegation to UNESCO.

The issuer is solely responsible for the content of this announcement.

Johnson Electric Hosts 2025 Humanoid Roundtable to Explore Hardware Standards in Next-Generation Humanoid Robotics

Leaders from seven humanoid manufacturers convene with hardware experts to discuss the future of humanoid hardware standardization


VANDALIA, OHIO Media OutReach Newswire – 14 May 2025 – Johnson Electric, a global leader in motion systems, hosted the inaugural 2025 Humanoid Roundtable on April 29 in Boston, MA, USA. The event brought together C-suite and technical executives in small to large humanoid manufacturers located across North America, Europe, and China.

Co-hosted by advanced technology experts, ESTAT Actuation, Netzer Precision, and IMSystems, the aim was to foster an open and informal discussion on the future of humanoid hardware standardization. Participants shared challenges, identified overlapping needs, and explored how shared standards might simplify integration and reduce costs. Top priorities included addressing recurring technical hurdles—such as motor-gearbox compatibility, connector reliability, and the lack of modular, off-the-shelf actuation systems.

“We found our hypothesis to be largely correct; in future humanoid platforms, differentiation will increasingly come from AI, training data, and application learning systems,” said Adam Stienecker, Director of Global Innovation at Johnson Electric.

That framing set the tone for a discussion that ranged from subsystem modularity to the broader need for scalable service infrastructure and commercialization strategies beyond the product itself. The challenges and priorities raised are now helping shape the focus of Johnson Electric’s follow-on event this September with A3, where the company will introduce its new joint solutions designed to reduce system cost and enable advanced functionality.

“There was a clear willingness to define what standards could look like—and to keep the conversation going. We’re looking forward to building on that momentum in September with A3, as plans are finalized.” said Carlos Richardson, roundtable emcee and Business Designer at Johnson Electric.

The 2025 Humanoid Roundtable is part of a broader industry effort to accelerate the path to scalable, serviceable, and commercially viable humanoid systems.

For interest related to humanoid joint systems, to speak into standardization, or to learn more, please contact the Johnson Electric team at innovation@johnsonelectric.com

Hashtag: #JohnsonElectric

The issuer is solely responsible for the content of this announcement.

About Johnson Electric

The Johnson Electric Group is a global leader in electric motors, actuators, motion subsystems and related electro-mechanical components. It serves a broad range of industries including Automotive, Smart Metering, Medical Devices, Business Equipment, Home Automation, Ventilation, White Goods, Power Tools, Lawn & Garden Equipment, and Warehouse Automation. The Group is headquartered in Hong Kong and employs more than 30,000 individuals in over 20 countries worldwide. Johnson Electric Holdings Limited is listed on The Stock Exchange of Hong Kong Limited (Stock Code: 179). For more information, visit .

*********

This press release contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected due to a variety of factors, including but not limited to technological challenges, market conditions, and regulatory developments.

Bora Pharmaceuticals Exits Integration Phase with Sequentially-Improved Gross and Operating Margins

Positioned to Unlock M&A Value through U.S. Manufacturing Amidst Geopolitical Complexities and Specialty Portfolio


HONG KONG SAR – Media OutReach Newswire – 14 May 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for first quarter of 2025.

Quarterly Business and Financial Highlights
  • Fueled by expanded capacity and new dosage forms, Bora’s CDMO business delivered a record high quarter, up 52.4% YoY and 3.0% QoQ.
  • As part of Bora’s long-term strategic growth plan, the Company is moving forward with a phased investment of tens of thousands US dollars to unlock the untapped potential of Maple Grove facility. This build-out is designed to enhance capabilities in oral solid dose and sterile manufacturing, strengthening the ability to support customer demand and scale future programs.
  • Pharma Sales revenues rose 82.0% YoY based on reported unaudited monthly sales, driven by strong performance from the vigabatrin franchise, which includes three dosage forms. Notably, VIGAFYDE captured over 70% share in the new patient segment.
  • Due to the completion of Plymouth area decommissioning, consolidated revenues for 1Q25 was NT$4.48 billion, a NT$350 million reversal from the unaudited monthly disclosures, all of which was attributed to the pharma sales segment.
  • Despite margin pressure from partial maintenance shutdowns at the Maryland sterile injectable site in early January and softening demand for generic product dexlansoprazole (DLS), product mix improvement from growing specialty portfolio lifted gross margin from the low of 4Q24 to 42.2% in 1Q25. Tech transfer for 6 Upsher-Smith generic products to cost-competitive sites within Bora network remains on track, with full transfer expected by year-end to support further margin recovery.
  • EPS from continuing operations reached NT$26.54, reflecting NT$2.44 billion of net non-operating income from the divestment of Bora Biologics and recognition of losses of Tanvex Biopharm. However, the decommissioning of the Plymouth area negatively impacted EPS by NT$12.99, resulting in a reported EPS of NT$13.55. Share capital increased 0.4% during the quarter from employee stock option exercises and convertible bond conversions.
  • DLS competitors began exiting the market in early 2Q25 due to supply chain hiccups, creating new opportunities for Bora to increase share and drive recovery momentum.
  • The Group remains optimistic that its first quarter restructuring efforts will increase the long-term value of its recent acquisitions, including unlocking NT$600 million in capital in 2025. CDMO business growth will be further accelerated with strategic U.S.-based capability and capacity.
Mr. Bobby Sheng, Chairman of Bora Group, stated, “The first quarter is the continuation of critical integration and restructuring phase following multiple business and capacity acquisitions in 2024, laying a solid foundation for operational efficiency expansion. Following substantial investments in the U.S last year, we did observe significant pressure in the U.S. generics space during Q4. This prompted us to swiftly accelerate our integration efforts. At the same time, evolving client dynamics and market demand have only strengthened our conviction in the long-term value and strategic role of these assets. While the organizational streamlining, business separation, and product portfolio optimization undertaken to reflect operational realities have created near-term hurdles, we remain confident that these actions are essential to achieving optimal resource allocation and hence satisfactory return on assets. These efforts are necessary steps in the Company’s path toward sustainable mid to long-term growth.

The closure of Plymouth area was completed ahead of schedule during the quarter and the area has thus been reclassified as discontinued operation in our quarterly financial statements altogether. From an operational standpoint, Bora has discontinued 15 products in the U.S. generics market along with the restructure, with an additional 6 products transferred to more cost-efficient manufacturing sites within the Group. On the financial side, discontinued operation resulted in a negative impact of approximately NT$1.34 billion, including overhead, inventory and equipment write-downs as well as severance-related expenses.
Looking ahead, Bora will advance its focus on high-value and complex dosage forms supported by over NT$5.0 billion cash on hand. At Maple Grove, 4 global pharmaceutical clients are currently in advanced discussions regarding CAPEX investments which we view as a strong validation of the site’s value and strategic fit. While the timeline for full deployment spans several years, we are approaching this expansion with operational discipline and commercial alignment to ensure its success over time.

On pharma sales side, Bora weathered softness in DLS demand in the first quarter but quickly gained market share as a competitor exited in early second quarter. Generic business rebounded in April, supported by strong sales from new 2024 launches including Potassium Chloride ER Tablets (KCL), and anti-angina drugs Diltiazem (DTC and DTS). This recovery underscores Bora’s agility and the resilience of the dual-engine strategy. Furthermore, we have successfully consolidated distribution network for specialty drugs. Bora expects its pediatric spasm product, VIGAFYDE (the 505(b)(2) oral solution), to extend its success in the new patient market into the switch segment in the very near future, supporting future margin and operational leverage expansion.

We continue executing on our goals to scale up, achieve more and integrate smarter, ensuring that both internal and external clients benefit from cost-efficient, regionally aligned manufacturing. By extending the strength of our dual-engine model, we believe Bora shall continue to create above-average total shareholder return.”

1Q2025 Operational Achievements & Full Year Outlook

Global CDMO Operations

Global CDMO Operations (excluding internal orders) delivered record-high revenues of NT$1.90 billion in the first quarter, up 52.4% YoY and representing approximately 39% of total revenue. Including internal orders, CDMO revenue reached NT$2.89 billion. A total of 600 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 30%, demonstrating strong clientele and advantage of scale. Bora CDMO continues to be a trusted partner for biotech and pharmaceutical innovators.

  • In 1Q25, the small molecule CDMO pipeline added US$123 million in potential orders and US$78 million in backlog, both marking historic highs.
  • CAPEX progress across sites reached approximately 50%, focused on debottlenecks, efficiency improvement, capacity increase and infrastructure upgrade to align with client and product needs. Flex Pro line at the Maryland sterile injectable facility was completed ahead of schedule and is expected to begin operations in early Q3.
  • Maple Grove launched its first CDMO project during the quarter and is currently negotiating with potential clients while evaluating CAPEX plans for differentiated dosage platforms. Overall, North American capacity transformation is progressing as planned.
  • Large molecule CDMO operation was launched following the January 20 reverse-acquisition of Bora Biologics by Tanvex Biopharm where Bora owns 30.5% of Tanvex. CDMO operations at the San Diego site are now active, and the ongoing 2,000L expansion has received strong interest from late-stage clients. Bora and Tanvex are actively pursuing U.S.-based commercial-scale manufacturing orders with a comprehensive one-stop service model.

Pharma Sales Operations

Pharma Sales Operations revenue reached NT$2.93 billion, representing 82.0% YoY growth and contributing approximately 61% of total revenue based on unadjusted numbers.

  • As the Upsher-Smith team continue to consolidate distributors for specialty drugs, we saw early signs of positive engagement from both market and payer channels at the end of the first quarter. Following the 2024 integration of TWi, Upsher-Smith and Pyros teams, Bora has established a focused pipeline in CNS specialty areas. The company expects to file its first self-developed 505(b)(2) submission for infantile spasms (Stiripentol) with the U.S. FDA by year-end, alongside other pipeline developments.
  • Pediatric epilepsy and TSC-related rare diseases represent the first wave of Bora’s pharma sales transformation targets. In addition to reducing over-reliance on generics, high-value rare disease and specialty drugs benefit from strong regulatory and payer support in the specialty pharmacy channel. These markets are less competitive with stable price, and offer targeted access to patient populations, allowing for meaningful long-tail value creation.
Recent Investor Conference

Bora will host an English online earnings call at 7:00 a.m. Taiwan time on May 15, 2025, followed by an investor conference hosted by Taishin Securities at the Grand Hyatt Taipei at 2:00 p.m. on May 16, 2025. Both events will cover the company’s Q1’25 financial and business results and outlook.

English Online Earnings Presentation Link: https://www.zucast.com/event/54SiM5il/subscribe/create

The 2025 Annual General Shareholders’ Meeting will be held on May 23 at the Tainan Guantian Industrial Marketing Center.

Bora will participate in the Jefferies Global Healthcare Conference in New York on June 4–5. For 1:1 meetings with management, please contact your Jefferies representative.

Bora 2025 Earnings Schedule

Q2 2025: Expected in the 3rd week of August 2025
Q3 2025: Expected in the 3rd week of November 2025
Q4 2025: Expected in the 2nd week of March 2026

Hashtag: #Bora

The issuer is solely responsible for the content of this announcement.

About Bora

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

Disclaimer:

This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.

Six Dead from Poisonous Mushrooms: Xayabouly Health Authorities Issue Urgent Warning

Six Dead from Poisonous Mushrooms: Xayaburi Health Authorities Issue Urgent Warning
Mushrooms (photo credit: Explore Laos)

On 13 May, the Xayabouly District Health Office issued a public warning following a series of mushroom poisoning cases that have resulted in six deaths across the province. The urgent notice calls for increased public awareness and preventive measures to avoid further fatalities.

Laos Launches Halal Certification Project to Boost Exports

“Development of Demonstration Companies Project for Enhancing Productivity for Halal Certification”. Vientiane Capital, Laos. 12 May 2025. (Photo credit: Ministry of Industry and Commerce)

Lao Micro, Small and Medium Enterprise (MSMEs) Promotion Agency has initiated a project to enhance the productivity of local manufacturers to meet Halal certification standards for exports.

The project, titled “Development of Demonstration Companies Project for Enhancing Productivity for Halal Certification,” was officially launched by the Minister of Industry and Commerce, Malaithong Kommasith, on 12 May. 

The Asian Productivity Organisation (APO) has allocated USD 130,000 to fund this one-year initiative.

During the ceremony, Minister Kommasith emphasized that improved productivity strengthens production capacity, enhances competitiveness, and promotes business sustainability while creating jobs and fostering innovation across sectors.

The project has selected three manufacturers with export potential targeting Muslim markets: Veunkham Salt Company, Somxay Coffee Company, and Dao Heuang Group.

In recent years, the Lao government has been making efforts to support potential MSMEs in obtaining certification for international standards, including Halal, to enhance their competitiveness in global markets. 

Halal certification is crucial for products targeting Muslim consumers, ensuring compliance with Islamic dietary laws and practices. The certification process involves rigorous standards for cleanliness, sourcing of raw materials, and ethical production practices.

The Lao government’s commitment to Halal certification aligns with broader regional efforts to tap into the growing demand for Halal products. 

For instance, during a bilateral meeting in June 2023, Laos expressed interest in forging cooperation with Malaysia’s Department of Islamic Development (Jakim) to obtain Halal certification for its products, aiming to develop the Halal industry in Laos.

Shortfall in Blood Donations Prompts New Push in Schools for 2025

Blood donation at Lao Red Cross. (Photo: Souliyasone Ngotsyoudom)

The Lao Red Cross is ramping up efforts to strengthen partnerships with schools and expand youth engagement in blood donation, following a shortfall in its 2024 collection targets. 

LINE NEXT and Kaia Expand Web3 and Stablecoin Adoption Across Asia Following a Native Deployment of Tether’s USD₮ on Kaia Blockchain


ABU DHABI, UAE – Media OutReach Newswire – 14 May 2025 – Tether, the largest company in the digital assets industry announced it has created a native deployment of Tether’s USD₮ on the Kaia blockchain – layer 1 blockchain that exclusively powers the Web3 Mini Dapp accessible within LINE Messenger by LINE NEXT. The collaboration is expected to deliver USD stablecoin offerings to more than 200 million Asia’s mainstream LINE users, enhancing the everyday application of digital assets.

Over 200 million LINE users will be able to utilize USD₮ for transactions right within the app without the need for any third party
Over 200 million LINE users will be able to utilize USD₮ for transactions right within the app without the need for any third party

LINE NEXT Inc. is LINE’s venture dedicated to developing and expanding the Web3 ecosystem. Currently, Kaia is exclusively powering the Mini Dapp and Dapp Portal ecosystem accessible within LINE Messenger. As part of this collaboration, USD₮ will be supported across LINE’s messenger-based Mini Dapp platform and self-custodial wallet infrastructure. As a result, by launching USD₮ on Kaia’s rapidly growing Web3 ecosystem, Tether broadens access to stable transactions of the world’s largest stablecoin to LINE’s 200 million monthly active user base. Meaning, users will be able to utilize USD₮ across Mini Dapps for in-app payments, cross-border transfers, and decentralized finance (DeFi) activities, all within the familiar LINE environment.

Mini Dapps built on the Kaia blockchain are set to introduce a wide range of features powered by USD₮, offering users a seamless digital asset experience within LINE Messenger.

Key features of LINE NEXT’s USD₮ initiatives include:

  1. Users can complete missions within various Mini Dapps and receive rewards in USD₮.
  2. Users can conveniently send and receive USD₮ with friends directly through the in-app wallet on LINE Messenger.
  3. Additional features under consideration by LINE NEXT include integrating USD₮ into Mini Dapp

The cryptocurrency market in Asia and Southeast Asia is experiencing rapid growth, emerging as a global hub for crypto adoption and trading. In Vietnam, Triple-A concluded Vietnam holds the second largest cryptocurrency market in ASEAN, with 21.2% of the population – around 20 million people, adopting crypto. In 2024, Vietnam ranked 5th globally in interest in digital assets, 3rd in using international trading platforms, and 6th in decentralized exchange (DEX) trading volume according to Chainalysis.

Among digital assets, USD₮ is widely used stablecoins by investors in cryptocurrency transactions, thanks to its price stability, high liquidity, and flexible convertibility. USD₮ is also widely supported by popular wallets such as Trust Wallet, Metamask, and locally used exchange wallets in Vietnam such as Remitano, ONUS.

With a large and growing user base, this partnership is expected to serve as a gateway for millions of everyday users across key markets in Asia, including Vietnam, to access on-chain finance.

“Tether’s native launch on Kaia is another step toward making stablecoins accessible to millions of mainstream users,” said Paolo Ardoino, Tether’s CEO. “Through LINE NEXT’s trusted blockchain infrastructure, over 200 million LINE users will now have a straightforward way to engage with digital assets in everyday life. Tether’s expansion to Kaia underscores its commitment to fostering stablecoin adoption across Asia and beyond.”

“Tether’s decision to natively launch USD₮ on Kaia will accelerate the spread of high-end USD-backed stablecoins in Asia, furthering our hybrid payment solutions in collaboration with LINE NEXT,” said Dr. Sam Seo, Chairman of Kaia DLT Foundation. “With the lowest transaction latency among EVM chains and immediate finality, Kaia’s USD₮ will provide the fastest, easiest, and most reliable user experience available across platforms such as LINE, DeFi, and CEXs.”

“LINE NEXT’s adoption of USD₮ will help establish a dollar-based gateway in Asia,” said Youngsu Ko, CEO of LINE NEXT. “By integrating stablecoin-powered services, we aim to bring Web3 services closer to users’ everyday experience.”
Positioned as a strategic gateway for USD-backed stablecoins in Asia, Kaia and LINE NEXT aim to facilitate the widespread circulation of USD₮ and lay the groundwork for USD₮-enabled Web3 services in the region.

The integration of Tether’s market leading stablecoin into Kaia’s robust blockchain and DeFi ecosystem streamlines on/offramps for fiat-to-digital asset conversion and helps drive LINE NEXT’s broader Web3 ambitions.

By bringing together LINE’s mainstream reach, Kaia’s blockchain scalability, and USD₮’s liquidity, this collaboration sets the stage for deeper financial inclusion and practical Web3 applications across Asia’s most active markets, including Japan, Thailand, and Taiwan.Hashtag: #Kaia #USD₮

The issuer is solely responsible for the content of this announcement.

About Tether and USDt

Tether is a pioneer in the field of stablecoin technology, driven by an aim to revolutionize the global financial landscape. With a mission to provide accessible and efficient financial, communication, artificial intelligence, and energy infrastructure. Tether enables greater financial inclusion, and communication resilience, fosters economic growth, and empowers individuals and businesses alike.

As the creator of the largest, most transparent, and liquid stablecoin in the industry, Tether is dedicated to building sustainable and resilient infrastructure for the benefit of underserved communities. By leveraging cutting-edge blockchain and peer-to-peer technology, it is committed to bridging the gap between traditional financial systems and the potential of decentralized finance.

About Kaia

Kaia is a high performance public blockchain that brings Web3 to the fingertips of hundreds of millions across Asia. Formed through the merger of the Klaytn and Finschia blockchains that were initially developed by Kakao and LINE respectively, Kaia is Asia’s largest Web3 ecosystem integrated with the Kakaotalk and LINE messengers that have a combined user base of over 250 million – all of whom can experience Web3 with the ease and speed of Web2 within their favourite messenger superapp to connect, create, collaborate, and contribute to the ecosystem. Learn more at .

About LINE NEXT Inc.

Based in the United States, LINE NEXT Inc. is focused on growing the global Web3 business. Through building a Web3 ecosystem, LINE NEXT aims to provide new digital experiences and lead the way into the future.

Mini Dapp

Mini Play, Big Reward! Experience seamless Web3 integration with Mini Dapp on LINE Messenger. Mini Dapp makes blockchain accessible to everyone, ensuring smooth onboarding, transactions, and rewards through Kaia’s blockchain infrastructure.

Mini Dapp Platform: Dapp Portal –

Laos Approves New Dry Port Project in Bolikhamxay

Laos Approves New Dry Port Project in Bolikhamxay. Bolikhamxay province. 09 May 2025. (Photo credit: Bolikhamxay newspaper)

Laos has taken a new step toward becoming a regional trade hub by leasing land for a new dry port next to the 5th Lao-Thai Friendship Bridge.

On 9 May, the Lao government signed an agreement to lease the land of 383,311 cubic meters to the local private company to build a new storage space.

This storage will be built in a village called Kuayoudom in the Paksan district. It will be right next to a new bridge between Laos’ Bolikhamxay province and Thailand’s Bueng Kan province, which is expected to be completed by the end of this year. 

The warehouse, places for trucks to unload, offices, and a shop have been built since 2023, now they are making it much bigger with more space for storing and moving goods.

The port is also located alongside Road No. 13, which has the highway project in the future, and a key route to connect Laos, Thailand, and Vietnam to the planned dry port in Laksao, Khamkeut district, as well as to the proposed Vientiane–Vietnam highway project.